Milestones

1. Application of single cell transcriptomics technologies in FFPE tissue, demonstrating its feasibility in routine clinical samples and allowing the identification of new tumor cell populations in breast and endometrial cancer.
2. Molecular characterization of relapses in breast and endometrial cancer with direct impact on the understanding of tumor progression and its clinical management. Identification of DLL3 as a biomarker of poor prognosis associated with high-grade tumors in medullary thyroid carcinoma through transcriptomic analysis and validation by immunohistochemistry.
3. Participation in the IMMUNE4ALL project to explore the viability of immunotherapy biomarkers in solid tumors of the ISCIII call for Personalized Medicine Research projects. Teams from the areas of Cancer (CIBERONC), Liver and Digestive Diseases (CIBEREHD), Rare Diseases (CIBERER) and Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) will collaborate in the project. Our group contributes to the integration of genomic, histopathological and clinical data into predictive models.
4. Consolidation of lines of research in digital pathology and artificial intelligence in collaboration with biomedical engineering groups, aimed at the development of advanced diagnostic and prognostic tools.
5. Strengthening the group through participation in scientific work groups: 1) Dr. Belén Pérez-Mies, coordinator of the breast work group of the Spanish Society of Pathological Anatomy; 2) Drs. Irene Carretero and Ignacio Ruiz, coordinators of the SEAP Joven working group, aimed at the promotion and development of young talents.